Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors

M. Takamatsu, T. Tsushima, Yasutomo Nasu, M. Noda, T. Saika, S. Kaku, H. Ohmori

Research output: Contribution to journalArticle

Abstract

In the present study, we assessed the effect of granulocyte colony-stimulating factor (G-CSF) on patients with advanced testicular tumors. The subjects were 24 patients with stage II B or higher, advanced testicular tumors treated in the Department of Urology, Okayama University Hospital during the 12-year period from 1980 to 1991 (5, stage II B and 19, stage III: 19 primary cases and 5 recurrent cases). We compared the intensity of the CDDP dose against prognosis in 24 patients, 12 of whom were treated prior to 1986 when G-CSF had not been available, the other 12 patients being treated after 1987 using G-CSF. The CDDP dose intensity was increased significantly from 16.9-32.2 mg/m2/wk (20.6 ± 6.2 mg/m2/wk, mean ± SD) to 20.9-37.0 mg/m2/wk (29.6 ± 5.2 mg/m2/wk) after the introduction of G-CSF (t-test, p <0.001). The 5-year survival rate was 40% in those patients treated without G-CSF as opposed to 90% after the introduction of G-CSF, and this result was statistically significant (logrank test, p = 0.04). Before the introduction of G-CSF, adverse reactions such as leukocytopenia forced us to reduce the doses and to change the schedules. Chemotherapy could be performed at full doses and on schedule due to the concomitant use of G-CSF, with the result that the therapeutic outcome was much improved.

Original languageEnglish
Pages (from-to)1508-1512
Number of pages5
JournalNishinihon Journal of Urology
Volume56
Issue number12
Publication statusPublished - 1994

Fingerprint

Testicular Neoplasms
Granulocyte Colony-Stimulating Factor
Therapeutics
Appointments and Schedules
Leukopenia
Urology
Survival Rate
Drug Therapy

Keywords

  • chemotherapy
  • dose intensity
  • testicular cancer

ASJC Scopus subject areas

  • Urology

Cite this

Takamatsu, M., Tsushima, T., Nasu, Y., Noda, M., Saika, T., Kaku, S., & Ohmori, H. (1994). Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors. Nishinihon Journal of Urology, 56(12), 1508-1512.

Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors. / Takamatsu, M.; Tsushima, T.; Nasu, Yasutomo; Noda, M.; Saika, T.; Kaku, S.; Ohmori, H.

In: Nishinihon Journal of Urology, Vol. 56, No. 12, 1994, p. 1508-1512.

Research output: Contribution to journalArticle

Takamatsu, M, Tsushima, T, Nasu, Y, Noda, M, Saika, T, Kaku, S & Ohmori, H 1994, 'Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors', Nishinihon Journal of Urology, vol. 56, no. 12, pp. 1508-1512.
Takamatsu M, Tsushima T, Nasu Y, Noda M, Saika T, Kaku S et al. Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors. Nishinihon Journal of Urology. 1994;56(12):1508-1512.
Takamatsu, M. ; Tsushima, T. ; Nasu, Yasutomo ; Noda, M. ; Saika, T. ; Kaku, S. ; Ohmori, H. / Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors. In: Nishinihon Journal of Urology. 1994 ; Vol. 56, No. 12. pp. 1508-1512.
@article{0163b6156b004d2da11d05dbced5c3b3,
title = "Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors",
abstract = "In the present study, we assessed the effect of granulocyte colony-stimulating factor (G-CSF) on patients with advanced testicular tumors. The subjects were 24 patients with stage II B or higher, advanced testicular tumors treated in the Department of Urology, Okayama University Hospital during the 12-year period from 1980 to 1991 (5, stage II B and 19, stage III: 19 primary cases and 5 recurrent cases). We compared the intensity of the CDDP dose against prognosis in 24 patients, 12 of whom were treated prior to 1986 when G-CSF had not been available, the other 12 patients being treated after 1987 using G-CSF. The CDDP dose intensity was increased significantly from 16.9-32.2 mg/m2/wk (20.6 ± 6.2 mg/m2/wk, mean ± SD) to 20.9-37.0 mg/m2/wk (29.6 ± 5.2 mg/m2/wk) after the introduction of G-CSF (t-test, p <0.001). The 5-year survival rate was 40{\%} in those patients treated without G-CSF as opposed to 90{\%} after the introduction of G-CSF, and this result was statistically significant (logrank test, p = 0.04). Before the introduction of G-CSF, adverse reactions such as leukocytopenia forced us to reduce the doses and to change the schedules. Chemotherapy could be performed at full doses and on schedule due to the concomitant use of G-CSF, with the result that the therapeutic outcome was much improved.",
keywords = "chemotherapy, dose intensity, testicular cancer",
author = "M. Takamatsu and T. Tsushima and Yasutomo Nasu and M. Noda and T. Saika and S. Kaku and H. Ohmori",
year = "1994",
language = "English",
volume = "56",
pages = "1508--1512",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "12",

}

TY - JOUR

T1 - Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors

AU - Takamatsu, M.

AU - Tsushima, T.

AU - Nasu, Yasutomo

AU - Noda, M.

AU - Saika, T.

AU - Kaku, S.

AU - Ohmori, H.

PY - 1994

Y1 - 1994

N2 - In the present study, we assessed the effect of granulocyte colony-stimulating factor (G-CSF) on patients with advanced testicular tumors. The subjects were 24 patients with stage II B or higher, advanced testicular tumors treated in the Department of Urology, Okayama University Hospital during the 12-year period from 1980 to 1991 (5, stage II B and 19, stage III: 19 primary cases and 5 recurrent cases). We compared the intensity of the CDDP dose against prognosis in 24 patients, 12 of whom were treated prior to 1986 when G-CSF had not been available, the other 12 patients being treated after 1987 using G-CSF. The CDDP dose intensity was increased significantly from 16.9-32.2 mg/m2/wk (20.6 ± 6.2 mg/m2/wk, mean ± SD) to 20.9-37.0 mg/m2/wk (29.6 ± 5.2 mg/m2/wk) after the introduction of G-CSF (t-test, p <0.001). The 5-year survival rate was 40% in those patients treated without G-CSF as opposed to 90% after the introduction of G-CSF, and this result was statistically significant (logrank test, p = 0.04). Before the introduction of G-CSF, adverse reactions such as leukocytopenia forced us to reduce the doses and to change the schedules. Chemotherapy could be performed at full doses and on schedule due to the concomitant use of G-CSF, with the result that the therapeutic outcome was much improved.

AB - In the present study, we assessed the effect of granulocyte colony-stimulating factor (G-CSF) on patients with advanced testicular tumors. The subjects were 24 patients with stage II B or higher, advanced testicular tumors treated in the Department of Urology, Okayama University Hospital during the 12-year period from 1980 to 1991 (5, stage II B and 19, stage III: 19 primary cases and 5 recurrent cases). We compared the intensity of the CDDP dose against prognosis in 24 patients, 12 of whom were treated prior to 1986 when G-CSF had not been available, the other 12 patients being treated after 1987 using G-CSF. The CDDP dose intensity was increased significantly from 16.9-32.2 mg/m2/wk (20.6 ± 6.2 mg/m2/wk, mean ± SD) to 20.9-37.0 mg/m2/wk (29.6 ± 5.2 mg/m2/wk) after the introduction of G-CSF (t-test, p <0.001). The 5-year survival rate was 40% in those patients treated without G-CSF as opposed to 90% after the introduction of G-CSF, and this result was statistically significant (logrank test, p = 0.04). Before the introduction of G-CSF, adverse reactions such as leukocytopenia forced us to reduce the doses and to change the schedules. Chemotherapy could be performed at full doses and on schedule due to the concomitant use of G-CSF, with the result that the therapeutic outcome was much improved.

KW - chemotherapy

KW - dose intensity

KW - testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=0028597926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028597926&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028597926

VL - 56

SP - 1508

EP - 1512

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 12

ER -